Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s targeting tumor-associated antigens...
Our promise to you:
Guaranteed product quality, expert customer support.
Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s targeting tumor-associated antigens can be infused into patients and attack the tumor. Chimeric Antigen Receptor (CAR) T cell therapy has shown great promise for cancer treatment.
The basic CAR structure consists of two fundamental domains: the extracellular antigen-binding domain and the intracellular signaling domain. The antigen-binding domain (scFv) commonly consisting of a variable heavy (VH) and a variable light (VL) chain, is derived from a monoclonal antibody (mAb). Common intracellular signaling domains include CD3ζ, CD28, 4-1BB and OX40.
Figure 1. Structure of a CAR
Lentiviruses are effective gene carriers leading to long-term gene expression. Lentiviral generated CAR-T cells targeting CD19 antigen have shown remarkable anti-tumor efficacy in clinical trials . Creative Biogene has developed CAR lentiviral packaging service based on most advanced techniques and extensive experience. We provide you one stop service from constructing the lentivirus expression vector to manufacture high-titer lentivirus particles. With years of experience in research of lentivirus, Creative Biogene provides convenient and efficient services for CAR lentiviral packaging service which have high safety profile and high efficiency of gene delivery to virtually all cell types and whole model organisms. Besides, we offer a wide selection range of CAR lentivirus particles in stock which can save your precious time and effort of constructing the lentivirus vector and packaging virus.
Creative Biogene’s CAR lentivirus packaging service has the following features:
|Target antigen||CAR systems||Type of tags||Type of promotor|
|2nd generation||3rd generation||4th generation||GFP||RFP||TRE||EF1α||CMV|